Psychiatr. praxi. 2016;17(2):44-47 | DOI: 10.36290/psy.2016.012

Biomarkers of schizophrenia - a brief review and the recent knowledge

prof. MUDr. Ladislav Hosák, Ph.D.
Psychiatrická klinika, Univerzita Karlova, Lékařská fakulta v Hradci Králové a Fakultní nemocnice Hradec Králové

Biomarker is a characteristic which is objectively measurable and assessable as the indicator of physiological biological processes, disease pathophysiology or treatment response. It may be defined at the molecular, cellular, organ or systemic levels. Biomarkers are divided into diagnostic, predictive, therapeutic, preventative and prophylactic ones. Thus, biomarker is an indicator which should help us correctly predict, diagnose, treat and prevent a given disease. In case of schizophrenia, no biomarker which can be applied in a routine clinical practice is recently available. An intensive research is going on, potential biomarkers in the field of genetics, epigenetics, metabolomics, electrophysiology and immunology seem to be promising. Schizophrenia is a complex disease, „panels“ of biomarkers instead of individual isolated findings should be sought for.

Keywords: schizophrenia, biomarker, diagnostics, treatment

Published: June 10, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hosák L. Biomarkers of schizophrenia - a brief review and the recent knowledge. Psychiatr. praxi. 2016;17(2):44-47. doi: 10.36290/psy.2016.012.
Download citation

References

  1. https://www.psychiatry.org/ (Consensus Report of the APA Work Group on Neuroimaging Markers of Psychiatric Disorders).
  2. Mirzakhanian H, Singh F, Cadenhead KS. Biomarkers in psychosis: an approach to early identification and individualized treatment. Biomark Med 2014; 8: 51-57. Go to original source... Go to PubMed...
  3. Stöber GS, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, et al. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psych 2009; 10: 127-155. Go to original source... Go to PubMed...
  4. Prata D, Mechelli A, Kapur S. Clinically meaningful biomarkers for psychosis: A systematic and quantitative review. Neurosci Biobehav Reviews 2014; 45: 134-141. Go to original source... Go to PubMed...
  5. Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W, et al. Methylome-Wide Association Study of Schizophrenia. Identifying Blood Biomarker Signatures of Environmental Insults. JAMA Psychiatry 2014; 71: 255-264. Go to original source... Go to PubMed...
  6. Guidotti A, Auta J, Davis JM, Dong E, Gavin DP, Grayson DR, et al. Toward the Identification of Peripheral Epigenetic Biomarkers of Schizophrenia. J Neurogenet 2014; 28: 41-52. Go to original source... Go to PubMed...
  7. Al Awam K, Haussleiter IS, Dudley E, Donev R, Brüne M, Juckel G, et al. Multiplatform metabolome and proteome profilig identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm 2015; 122: S111-S122. Go to original source... Go to PubMed...
  8. Xiong P, Zeng Y, Wu Q, Huang DXH, Zainal H, Xu X, et al. Combining Serum Protein Concentrations to Diagnose Schizophrenia: A Preliminary Exploration. J Clin Psychiatry 2014; 75: e794-e801. Go to original source... Go to PubMed...
  9. Fuggetta G, Bennett MA, Duke PA, Young AMJ. Quantitative electroencephalography as a biomarker for proneness toward developing psychosis. Schizophr Research 2014; 153: 68-77. Go to original source... Go to PubMed...
  10. Arai M, Miyashita M, Kobori A, Toriumi K, Horiuchi Y, Itokawa M. Carbonyl stress and schizophrenia. Psychiatry Clin Neurosciences 2014; 68: 655-665. Go to original source... Go to PubMed...
  11. Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: An overview. Psychiatry Research 2014; 216: 277-285. Go to original source... Go to PubMed...
  12. Hosák L, Kovařík A, Ustohal L, Látalová K. Duševní poruchy - epigenetické mechanizmy jejich vzniku a farmakologické léčby. Psychiatrie pro praxi 2015; 16: 45-48.
  13. Kay YC, Ko CY, Wang SC, Liu YP. Protective Effects of Quetiapine on Metabolic and Inflammatory Abnormalities in Schizophrenic Patients during Exacerbated Stage. Chin J Physiol 2016 (v tisku).
  14. Lai C, Scarr E. Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics. World Journal of Psychiatry 2016 (v tisku). Go to original source...
  15. Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, et al. Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis of Multivariate Pattern Recognition Studies. Neuropsychopharmacology 2015; doi:10.1038/npp.2015. 22. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.